Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride
NCT03890055
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Small Cell Lung Cancer
Interventions
DRUG:
Anlotinib Hydrochloride
Sponsor
Chifeng Municipal Hospital